Alnylam and Sanofi report RNAi success | September 25, 2017 Issue - Vol. 95 Issue 38 | Chemical & Engineering News
Volume 95 Issue 38 | p. 13 | Concentrates
Issue Date: September 25, 2017

Alnylam and Sanofi report RNAi success

Department: Business
Keywords: Nucleic acids, RNAi, rare disease, Alnylam

Patisiran, an RNA interference drug being developed by Alnylam and Sanofi, met its primary goals in a Phase III study as a treatment for hereditary ATTR amyloidosis, a rare genetic disease. Alnylam plans to file a New Drug Application later this year. “We are proud to report the first-ever positive Phase III results for an RNAi therapeutic,” says Alnylam CEO John Maraganore. Alnylam’s stock price soared more than 20% on the news. The firm earlier experienced setbacks for two other RNAi drugs, revusiran and fitusiran.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment